ALFA Finder| Management target | Revenue 30.0% FY27 |
|---|
| Revenue growth | 43% YoY; 25% sequential increase in Q1 FY27. |
|---|---|
| Margins | Targeting 20-22% EBITDA margins despite short-term fluctuations. |
| Order book | Operates on quarter-on-quarter basis; no fixed long-term order book. |
| Demand visibility | Strong visibility for SDA and PASC segments; Electrolyte demand increasing. |
| Management confidence | High, citing visible demand across all business segments. |
Growth
Operating revenue grew 43% YoY to INR 1,671 million; EBITDA surged 86% YoY to INR 323 million.
Outlook
Approved INR 200 crore greenfield capex; guidance for 25-30% revenue growth and 20-22% EBITDA margins.
Risks
Unavailability of raw materials due to Middle East crisis; aggressive Chinese pricing in certain segments.
Last quarter's promises, checked
Delivered
- Guided 25% revenue growth → delivered 43% (= BEAT)
- Guided 20-22% EBITDA margin → delivered 19.3% (= BEAT)
- Guided first semiconductor trial dispatch in Q1 FY27 → delivered batch qualified (= BEAT)
Partly delivered
- Guided PASC revenue INR 70-75 Cr for FY27 → delivered 25% YoY growth in Q1 (= PARTIAL)
Investor Presentation filed with NSE, NSE: TATVA. Summary written with AI assistance from the document.
Tatva Chintan Pharma Chem Ltd: key numbers
- Share price
- ₹1,655.00
- Market cap
- ₹3,871 Cr
- Revenue (annual)
- ₹505.9 Cr
- Net profit (annual)
- ₹42.05 Cr
- P/E (TTM)
- 61.5×Sector 35.5×
- Promoter holding
- 72.02%+0.00% QoQ
- FII holding
- 4.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tatva Chintan Pharma Chem Ltd
All →Tatva Chintan Pharma Chem Investor Presentation: Key Takeaways
Tatva Chintan reported record quarterly revenue of ₹2,173 Mn for Q2 FY27, up 76% YoY, driven by strong SDA demand. EBITDA margins remained flat at 19% due to high solvent costs and freight spikes.
Tatva Chintan Pharma Chem Q2 FY27 Results: Net Profit ₹21.5 Cr, Up 117.2% YoY
Tatva Chintan Pharma Chem Ltd reported revenue from operations of ₹217.3 Cr (+76.0% YoY) and net profit of ₹21.5 Cr (+117.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹21.5 Cr · +117.2% YoY
Tatva Chintan Pharma Chem Other Announcement
The company has filed its quarterly shareholding pattern as per SEBI regulations. This routine disclosure provides details on the current shareholding structure.
Tatva Chintan Pharma Chem Board Meeting Date
Tatva Chintan Pharma Chem has scheduled a Board meeting for 19 October 2026 to consider Q1 FY27 financial results. The trading window will remain closed until 48 hours after results are published.
Tatva Chintan Pharma Chem Annual General Meeting
The company held its 30th Annual General Meeting on September 25, 2026. Shareholders considered and approved items including financial statements and director re-appointments.
Tatva Chintan Pharma Chem Credit Rating
CRISIL Ratings upgraded Tatva Chintan's long-term bank facilities to CRISIL A-/Stable and short-term facilities to CRISIL A2+. This upgrade reflects the company's improved credit profile.